Skip to main content

Advertisement

Log in

Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The objective of this study was to conduct a randomised phase II study in second-line metastatic colorectal cancer with the purpose of confirming preliminary clinical data indicating that the formulation of irinotecan with the drug carrier, hyaluronan (HA) reduced toxicity of the drug.

Methods

Irinotecan-naïve patients were randomized to receive either irinotecan (350 mg/m2) or HA-Irinotecan (HA 1,000 mg/m2 and irinotecan at 350 mg/m2) every 3 weeks for a maximum of eight cycles.

Results

Seventy-six patients (41 HA-Irinotecan and 35 irinotecan-alone) were enrolled. There was no significant difference in any individual, or overall, grade 3 or 4 toxicity. There was a trend for increased diarrhea in the HA-Irinotecan-treated patients (20 versus 9%; P = 21), potentially explained by a disproportionate number of baseline toxicity-associated risk factors in this treatment group. The median number of cycles completed was six for HA-Irinotecan patients and two for irinotecan-alone patients (P = 0.005). When compared to the control arm, HA-Irinotecan patients had a significantly longer median progression-free survival of 5.2 versus 2.4 months (P = 0.017) and time to treatment failure (4 vs. 1.8 months; P = 0.007). Median overall survival was 10.1 months for HA-Irinotecan compared to 8.0 months for irinotecan patients (P = 0.196).

Conclusion

Further studies are required to define the safety of the formulation of irinotecan with HA. While this study was not adequately powered to demonstrate survival differences, these phase II data indicated HA-Irinotecan to be a promising therapy demonstrating improved efficacy compared to irinotecan-alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807–814

    Article  CAS  PubMed  Google Scholar 

  2. Scott JE, Cummings C, Brass A, Chen Y (1991) Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowing-electron microscopy and computer simulation. Hyaluronan is a very efficient network-forming polymer. Biochem J 274(Pt 3):699–705

    CAS  PubMed  Google Scholar 

  3. Scott JE, Heatley F (1999) Hyaluronan forms specific stable tertiary structures in aqueous solution: a 13C NMR study. Proc Natl Acad Sci USA 96:4850–4855

    Article  CAS  PubMed  Google Scholar 

  4. Asplund T, Heldin P (1994) Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res 54:4516–4523

    CAS  PubMed  Google Scholar 

  5. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241–319

    Article  CAS  PubMed  Google Scholar 

  6. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM (2005) Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 47:420–428

    Article  CAS  PubMed  Google Scholar 

  7. Makrydimas G, Zagorianakou N, Zagorianakou P, Agnantis NJ (2003) CD44 family and gynaecological cancer. In Vivo 17:633–640

    CAS  PubMed  Google Scholar 

  8. Culty M, Shizari M, Thompson EW, Underhill CB (1994) Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol 160:275–286

    Article  CAS  PubMed  Google Scholar 

  9. Brown TJ, Falzon J, Pho M, Hatherell E, Vaghela V, Wilson J, Fox R, Gibbs P, Rosenthal M, Fraser J, Brownlee G (2005) The development of hyaluronic acid as a targeted transport vehicle for chemotherapeutic drugs. In: Balazs EA, Hascall VC (eds) Hyaluronan: structure, metabolism, biological activities. therapeutic applications, Edition. Matrix Biology Institute, New Jersey, pp 421–433

    Google Scholar 

  10. Gibbs P, Brown TJ, Ng R, Jennens R, Cinc E, Pho M, Michael M, Fox RM (2008) A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-Fluorouracil metastatic colorectal cancer patients. Chemotherapy 55:49–59

    Article  PubMed  Google Scholar 

  11. Rosenthal MA, Gibbs P, Brown TJ, Wong S, Uren S, Ellis A, Li L, Heldin P, Poliviou H, Fox RM (2005) Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. Chemotherapy 51:132–141

    Article  CAS  PubMed  Google Scholar 

  12. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418

    Article  CAS  PubMed  Google Scholar 

  13. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412

    Article  CAS  PubMed  Google Scholar 

  14. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260

    CAS  PubMed  Google Scholar 

  15. Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H, Tsipras H, Polyzos A (2003) Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother Pharmacol 52:514–519

    Article  CAS  PubMed  Google Scholar 

  16. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H (1999) Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 35:54–59

    Article  PubMed  Google Scholar 

  17. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6:2236–2244

    CAS  PubMed  Google Scholar 

  18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  19. Mick R, Gupta E, Vokes EE, Ratain MJ (1996) Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012–2019

    CAS  PubMed  Google Scholar 

  20. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151–5159

    Article  CAS  PubMed  Google Scholar 

  21. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329–332

    Article  CAS  PubMed  Google Scholar 

  22. Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27:717–731

    Article  PubMed  Google Scholar 

  23. Fraser JRE, Engström-Laurent AU, Laurent GB (1984) Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 11:17–25

    Article  CAS  PubMed  Google Scholar 

  24. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319

    Article  CAS  PubMed  Google Scholar 

  25. Tournigand C, de Gramont A (2006) Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer. Bull Cancer 93(Suppl 1):S11–S15

    CAS  PubMed  Google Scholar 

  26. Di Fiore F, Van Cutsem E, Laurent-Puig P, Siena S, Frattini M, De Roock W, Lièvre A, Sartore-Bianchi A, Bardelli A, Tejpar S (2008) Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. J Clin Oncol 26 (May 20 suppl; abstr 4035)

  27. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515

    Article  PubMed  Google Scholar 

  28. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130–1136

    Article  CAS  PubMed  Google Scholar 

  29. Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, Gruia G, Mourier A, Sibaud D, Lefebvre P, Beijnen JH, Schellens JH, ten Bokkel Huinink WW (2004) A randomized phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 91:1434–1441

    CAS  PubMed  Google Scholar 

  30. Mathijssen RH, Verweij J, Loos WJ, de Bruijn P, Nooter K, Sparreboom A (2002) Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. Br J Cancer 87:144–150

    Article  CAS  PubMed  Google Scholar 

  31. Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H (2005) Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 92:1055–1062

    Article  PubMed  Google Scholar 

  32. Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA (2002) Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs 13:139–140

    Article  CAS  PubMed  Google Scholar 

  33. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14:2688–2695

    CAS  PubMed  Google Scholar 

  34. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A (2000) Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 6:3451–3458

    CAS  PubMed  Google Scholar 

  35. Sparreboom A, Kehrer DF, Mathijssen RH, Xie R, de Jonge MJ, de Bruijn P, Planting AS, Eskens FA, Verheij C, de Heus G, Klaren A, Zhang S, Verhaeghe T, Palmer PA, Verweij J (2004) Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. Br J Cancer 90:1508–1515

    Article  CAS  PubMed  Google Scholar 

  36. Tobin PJ, Beale P, Noney L, Liddell S, Rivory LP, Clarke S (2006) A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol 57:309–316

    Article  CAS  PubMed  Google Scholar 

  37. Tobin P, Clarke S, Seale JP, Lee S, Solomon M, Aulds S, Crawford M, Gallagher J, Eyers T, Rivory L (2006) The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. Br J Clin Pharmacol 62:122–129

    Article  CAS  PubMed  Google Scholar 

  38. Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A (2006) Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. Cancer Chemother Pharmacol 58:585–593

    Article  CAS  PubMed  Google Scholar 

  39. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 20:3293–3301

    Article  CAS  PubMed  Google Scholar 

  40. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ (2001) Modulation of irinotecan-induced diarrhea by co treatment with neomycin in cancer patients. Clin Cancer Res 7:1136–1141

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Alchemia Oncology Pty Ltd, Brisbane, Australia.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tracey J. Brown.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibbs, P., Clingan, P.R., Ganju, V. et al. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol 67, 153–163 (2011). https://doi.org/10.1007/s00280-010-1303-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1303-3

Keywords

Navigation